From July 29 to 31, 2025, the 77th ADLM Exhibition (formerly AACC) was held in Chicago, USA. Biotest Biotech, alongside its American subsidiary ADVIN BIOTECH, made a dazzling appearance with its innovative product portfolio and solutions. As a premier global event in the clinical laboratory field, the ADLM Exhibition brought together top industry experts and cutting-edge technologies, showcasing the latest advancements in clinical laboratory testing equipment and in vitro diagnostic products worldwide.

At this year’s exhibition, Biotest and ADVIN BIOTECH unveiled a series of new products and technologies, driven by innovation and technical excellence. These included the FluidicNow™ microfluidic immunoassay technology, the SalivaTracer series for trace saliva drug testing, the SafeVin™ series for beverage drug testing, the DiagPal™ series Lateral Flow Reader, and COVID-19 +Flu A&B+RSV Antigen Combo Rapid Test. Most of these products were launched for the first time in the Americas region . Their advanced technology and outstanding performance captivated numerous attendees, making them one of the highlights of the event. Among them, the FluidicNow™ microfluidic immunoassay platform stood out particularly, featuring integrated high-sensitivity sensors, rapid reaction systems, and flexible test menu designs. It not only met the multi-level needs of various laboratories, but also earned high praise from professional audiences for its exceptional performance in emergency and critical care scenarios.

On-site, Biotest and ADVIN BIOTECH’s professional team engaged in in-depth discussions with diagnostic reagent distributors and medical experts from around the world. These interactions not only provided precise insights into the demands and trends of key North American markets but also yielded forward-looking feedback on new product development, offering clear direction for the company’s future 510K product strategy. Additionally, through multi-round, cross-regional dialogues, the team systematically analyzed the differentiated needs of the Latin American market—including healthcare resource distribution, insurance payment systems, user operating habits, and product preferences—and developed a tailored "one-place-one-policy" solution framework accordingly.

Amid the new landscape of global competition, Biotest leveraged ADLM 2025 as a strategic pivot to comprehensively upgrade its international operations. With ADVIN BIOTECH as a localized platform, the company is expanding its reach across North and Latin American markets, continuously enhancing its global market responsiveness. Moving forward, Biotest remains committed to its founding principle of "driving industry progress through technological innovation." By focusing on unmet clinical needs and sustaining R&D investment and product iteration, the company aims to provide global healthcare institutions with more accurate and reliable diagnostic tools. Through these efforts, Biotest actively embodies its mission of "Health Without Borders," contributing the wisdom and strength of a Chinese enterprise to the global health community.